An Exploratory Study of A-337 in the Management of Malignant Solid Dose Escalation and Expansion Phases
Title: An Exploratory Study of A-337 in the Management of Malignant Solid Dose Escalation and Expansion Phases
Recurrent or Metastatic Solid Tumors
BIOLOGICAL: Recombinant Anti-EpCAM-CD3 Antibody Injection
Evaluate the Incidence and Characteristics of Adverse Events of A-337 in the Treatment of malignant Solid Tumors, Incidence and characteristics of adverse events, At the end of Cycle 1 (each cycle is 28 days)|Evaluate the MTD and DLT of A-337 in the Treatment of malignant Solid Tumors, dose limited toxicity(DLT), maximum tolerance dose(MTD), At the end of Cycle 1 (each cycle is 28 days)
Evaluate the PK(Cmax) of A-337 in the Treatment of malignant Solid Tumors, Cmax, At the end of Cycle 3 (each cycle is 28 days)|Evaluate the PK(Tmax) of A-337 in the Treatment of malignant Solid Tumors, Tmax, At the end of Cycle 3 (each cycle is 28 days)|Evaluate the PK（T1/2) of A-337 in the Treatment of malignant Solid Tumors, T1/2, At the end of Cycle 3 (each cycle is 28 days)|Evaluate the PK(Vd) of A-337 in the Treatment of malignant Solid Tumors, Vd, At the end of Cycle 3 (each cycle is 28 days)|Evaluate the PK(CL/F) of A-337 in the Treatment of malignant Solid Tumors, CL/F, At the end of Cycle 3 (each cycle is 28 days)|Evaluate the PK(MRT) of A-337 in the Treatment of malignant Solid Tumors, MRT, At the end of Cycle 3 (each cycle is 28 days)|Evaluate the PK(AUC) of A-337 in the Treatment of malignant Solid Tumors, AUC, At the end of Cycle 3 (each cycle is 28 days)|Evaluate the efficacy evaluation（ORR） of A-337 in the Treatment of malignant Solid Tumors, ORR, At the end of each Cycle (each cycle is 28 days)|Evaluate the efficacy evaluation（DCR） of A-337 in the Treatment of malignant Solid Tumors, DCR, At the end of each Cycle (each cycle is 28 days)|Evaluate the efficacy evaluation（DDC） of A-337 in the Treatment of malignant Solid Tumors, DDC, At the end of each Cycle (each cycle is 28 days)|Evaluate the efficacy evaluation（PFS） of A-337 in the Treatment of malignant Solid Tumors, PFS, At the end of each Cycle (each cycle is 28 days)|Evaluate the efficacy evaluation（OS） of A-337 in the Treatment of malignant Solid Tumors, OS, At the end of each Cycle (each cycle is 28 days)
Protocol Number: IM-2021A Study Stage: Phase I Study Number: 2-3 sites Subject Number: up to 94 patients with recurrent or metastatic solid tumors, for whom there are no available effective standard treatments or for whom standard treatments have proven ineffective or intolerable.